Compare Enveric Biosciences Inc (ENVB) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Expeditors International of Wshngtn Inc — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.80M), while Expeditors International of Wshngtn Inc trades at $193.24 (market cap $25.18B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 3702.9× Enveric Biosciences Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.84% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Expeditors International of Wshngtn Inc for 43 Days on average.
| ENVB | EXPD | |
|---|---|---|
Market Cap | $6.80M | $25.18B |
Volume | 64,867 | 1,003,557 |
Sector | Health | Industrials |
52-Week High | $10.80 | $194.12 |
52-Week Low | $1.27 | $113.13 |
Typical Hold Time | 14 Days | 43 Days |
Enterprise Value | -$1.49M | $24.72B |
Dividend Yield | — | 0.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.45, down 3.01% today, with a bearish technical signal from moving averages. The company shows negative profitability metrics with ROE at -235.48% and ROA at -193.53%, though it has consistently beaten EPS estimates in recent quarters. Recent positive developments include new patent allowances and preclinical data supporting its non-hallucinogenic drug candidates.
The outlook remains speculative given the lack of revenue and negative cash flow from operations, offset by strong analyst buy ratings (75%). Key risks include clinical trial outcomes and funding needs, while catalysts hinge on regulatory progress and successful drug development in the competitive biotech space.
EXPD trades at $193.24, up 1.25% with a bullish technical signal. The stock shows strong fundamentals with three consecutive earnings beats and robust profitability metrics including 42.6% ROE. Recent news highlights efficiency initiatives and airfreight demand strength. Moving averages signal bullish momentum while oscillators remain neutral.
Outlook remains positive with earnings momentum and operational efficiency gains, though valuation appears stretched at 28.2 P/E. Risks include competitive pressures and potential freight market volatility. Analyst consensus is cautious with 63.6% hold ratings and $179.43 price target below current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
